
Opinion|Videos|December 18, 2024
Clinical Decision-Making for a Patient With eBC: Scenario and Strategies
Author(s)Kevin Kalinsky, MD, MS, Virginia Kaklamani, MD
Panelists discuss how differences in trial designs, including inclusion criteria, dosing, and end points, influence clinical decision-making in the use of CDK4/6 inhibitors for HR+/HER2– early breast cancer (eBC), with a focus on the NATALEE trial’s analysis of patients with no or low nodal involvement, and how recent expanded approval of ribociclib for high-risk node-positive and node-negative eBC patients guides the identification of ideal candidates based on clinical factors.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please describe notable differences in the trial designs or analyses (eg, inclusion criteria, dosing, end points) with these CDK4/6 inhibitors in eBC.
- How do these differences impact your clinical decision-making?
- The latest NATALEE trial analysis (N0 subgroup) examines patients with no or low nodal involvement; can you please describe your experience with this patient population?
- With the recent expanded approval of ribociclib for node-positive and node-negative HR+/HER2– eBC patients with a high risk of recurrence, what patient characteristics or clinical factors make someone an ideal candidate for adjuvant ribociclib?
Advertisement
Related to this article

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.

The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.

Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.

Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5

